Health In Tech, Inc.HIT

Health In Tech, Inc. is a Nevada-registered company whose public materials promise brokers and employers a “single standardized transaction platform” for quoting, binding and paying health plans, while its latest 10-Q shows a business that is still burning cash faster than its eDIYBS engine can quote a plan.

The glossy product pages for eDIYBS and HI Card describe a frictionless world where brokers can underwrite groups in minutes and every stakeholder sees the same real-time patient data, yet the 10-Q for the quarter ended 31 March 2026 records just $8.8m in revenue against a $1.6m net loss and a $3.3m outflow from operating activities. Research and development ate $920k of that cash, leaving the company with $10.3m in the bank and $7.4m of liabilities-equity of $21.6m that rests on 35 cents of cash per dollar rather than on proven scale. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/2019505/000121390026079326/xslF345X06/ownership.xml)

The company’s 8-K filings from 13-14 May 2026 are framed as forward-looking management discussions rather than as hard-score updates; they mention “possible or assumed operational results” and competitive risks but do not file new revenue, cash or customer counts. The HI Card and eDIYBS web pages remain the primary public evidence of product functionality, yet neither page supplies audited usage metrics, customer counts, or monetisation details to corroborate the brochure. (source: SEC EDGAR 8-K filed 2026-05-13, https://www.sec.gov/Archives/edgar/data/2019505/000121390026055977/ea0290605-8k_health.htm)

The latest balance-sheet snapshot (31 March 2026) shows assets of $29.0m, liabilities of $7.4m, and stockholders’ equity of $21.6m, with $10.3m in cash and cash equivalents. Operating cash flow was -$3.3m for the quarter; net income attributable to parent was -$1.6m; diluted EPS was -$0.03 on 57.4m weighted average shares outstanding; and R&D expense was $920k. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/2019505/000121390026079326/xslF345X06/ownership.xml)

For readers seeking a live quote or chart, the SEC filings do not provide a trading venue or ticker; the company’s shares trade OTC in the United States under the symbol HITI, but the evidence set above is drawn solely from SEC EDGAR filings and the company’s own product pages and does not include any market-price or liquidity analysis. (source: SEC EDGAR index for CIK 2019505, https://www.sec.gov/edgar/browse/?CIK=2019505)

What changed this week: the company hosted a conference call on 14 May 2026 to discuss financial and operating results, but the call script and subsequent filings reiterate the same forward-looking language without supplying fresh operating metrics, customer wins, or cash-flow milestones. The only numerical update remains the 10-Q snapshot for Q1 2026, which the company filed on the usual schedule. (source: SEC EDGAR 8-K filed 2026-05-14, https://www.sec.gov/Archives/edgar/data/2019505/000121390026056014/ea0290620-8k_health.htm)

What remains unproven: audited customer counts, average revenue per customer, gross margins on level-funded plans, and any sustained path to positive operating cash flow. The product pages and press materials describe functionality and promise speed, but no filed document yet quantifies adoption, retention, or unit economics. Until such metrics appear, the gap between platform story and ledger persists. (source: company product pages at https://healthintech.com/solutions/ediybs/ and https://healthintech.com/solutions/hicard/)